ABSA International
ABSA International

Resources with keywords: vaccination



Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 (NEW 8/3, Website, Publication)
CDC/MMWR
30 July 2021

Brown CM, Vostok J, Johnson H, et al.

Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category, National Healthcare Safety Network — United States, March 2021 (NEW 8/3, Website, Publication)
CDC/MMWR
30 July 2021

Lee JT, Althomsons SP, Wu H, et al.

Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage (NEW 8/3, Website, Publication)
CDC/MMWR
27 July 2021

Christie A, Brooks JT, Hicks LA, et al.

Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk (NEW 8/3, Website, Publication)
JAMA Pediatrics
6 July 2021

Yarden Golan PhD, Mary Prahl MD, Arianna Cassidy MD, et al

Vaccine-associated mRNA was not detected in 13 milk samples collected 4 to 48 hours after vaccination from 7 breastfeeding individuals.

EEOC Issues Updated COVID-19 Technical Assistance (NEW 6/8, Website, Regulatory)
U.S. Equal Employment Opportunity Commission (EEOC)
28 May 2021

Provides additional information on vaccinations in the employment context.

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination
Human Vaccines & Immunotherapeutics
12 May 2016

Baldo A, Galanis E, Tangy F, Herman P.
The use of recombinant MV vector has to comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The present article highlights the main characteristics of MV and recombinant MV vectors used for vaccination and virotherapy and discusses these features from a biosafety point of view.

Go to Top